Should your clinical trial be adaptive?
Trials that include a prospectively planned modification based on an interim analysis, otherwise known as adaptive trials, are often associated with greater efficiency and better prospects for patients without compromising statistical rigor. And new holistic approaches to creating these designs are making room for transformative, even revolutionary, changes to strategic drug development. But does this approach make sense for your trial? Consider this ten-point decision framework:
1. Are there any regulatory concerns or complexities?
2. Is there any reason to believe that decision-making will be driven by population enrichment, biomarkers, or surrogates?
3. What are the resource constraints in areas such as drug supply and enrollment?
4. Can the data monitoring committee receive and evaluate data in a timely manner?
5. Is statistical expertise available to you?
6. Are forecasting tools available to you?
7. How would adaptive designs optimize your financial strategy?
8. What are the statistical needs?
10. Will historical or real-world data be helpful in supporting regulatory submissions?For more details on each step of this framework as well as an overview of the scientific, financial, strategic, and ethical benefits of adaptive trials, download our white paper “Adaptive Trials at the Mainstream of Drug Development” below:
The Winter Weekends Reads series features complimentary publications on a variety of topics on clinical trial design and data science. Subscribe to our weekly newsletter below and never miss a post!
Learn more about adaptive trials in Perspectives on Enquiry & Evidence:
If you'd like updates on our blog posts, sign up for email updates below.
